TMiRob

TMiRob (Shanghai TMI Robotics Technology Co., Ltd.) focuses on intelligent robot solutions for healthcare environments. Founded in January 2015, the company has deployed its systems across more than 400 large-scale tertiary hospitals in 28 provinces and municipalities throughout China, establishing itself as a significant player in the medical service robotics sector.

Company Overview

Pan Jing, the company’s founder and chairman, brings extensive experience in robotics control systems and algorithm development. The founding team spent two months conducting field investigations in hospitals before developing their initial product concepts, identifying critical pain points in operating room logistics and nuclear medicine ward services.

TMiRob was designated as a national-level “Little Giant” enterprise under China’s Specialized, Refined, Differentiated, and Innovative (SRDI) program in 2021. The company holds 255 patents and maintains a research and development team comprising approximately 70% of total staff.

Core Products

Intelligent Disinfection Robot

The company’s flagship disinfection robot integrates three disinfection modes: ultraviolet-C (UVC) light, ultra-dry atomized hydrogen peroxide, and plasma air filtration. This system achieved a pathogen elimination rate of 99.9999%, including bacterial endospores. It was the first robot in China to receive a disinfection device registration certificate.

Automated Delivery Robot System

The hospital logistics system handles automated delivery of medical supplies across surgery rooms, pharmacy intravenous admixture services (PIVAS), laboratories, and inpatient pharmacy departments. The system supports controlled substance delivery including narcotics, Class I and II psychotropic drugs, and temperature-sensitive medications.

Nuclear Medicine Ward Service Robot

This product addresses radiation exposure concerns for medical staff in nuclear medicine departments. The robot provides remote patient care services including medication delivery, health monitoring, and telemedicine consultations in isolation wards, reducing staff exposure to radioactive patients.

Intelligent Medical Service Robot

Combining AI, face recognition, voice interaction, remote video, and multimedia capabilities, this platform provides targeted services based on specific departmental requirements.

Technology & Innovation

TMiRob’s technical foundation includes proprietary autonomous navigation algorithms, SLAM (Simultaneous Localization and Mapping), obstacle avoidance systems, and human-computer interaction capabilities. The company applies digital twin technology and AI to create integrated smart hospital solutions.

Key technical achievements include:

• Pedestrian detection system that automatically disables UV mode when personnel enter the disinfection zone
• Autonomous charging and route optimization
• Fleet management software for multi-robot coordination
• Radiation monitoring integration for nuclear medicine applications

Market Presence

The company’s systems operate in over 400 large tertiary hospitals across China, including Wuhan Union Hospital (one of the first deployment sites in 2016), Shanghai Renji Hospital, the First Affiliated Hospital of Zhengzhou University, and Anhui Provincial Hospital.

During the COVID-19 pandemic outbreak in early 2020, TMiRob delivered 42 disinfection robots to Hubei province hospitals within weeks, representing one-sixth of the company’s monthly production capacity at that time. The company’s monthly production capacity reached 300 units.

Smart Hospital Solutions

TMiRob has expanded from individual robot products to full smart hospital systems:

• Smart Operating Room: Integrated supply management and instrument tracking
• Smart ICU: Automated disinfection and monitoring
• Smart Ward: Patient service and logistics automation
• Smart Outpatient: Service and navigation assistance

Key Milestones

• 2015: Company founded in Shanghai
• 2016: First patent for invention obtained; trial deployment at Wuhan Union Hospital
• 2016: Angel round funding (RMB 10M)
• 2017: Series A funding (RMB 40M) led by IDG Capital
• 2018: Series B funding (RMB 200M) led by Jinpu Investment
• 2019: Series B+ round completed
• 2020: Rapid deployment supporting COVID-19 response
• 2021: Designated national SRDI “Little Giant” enterprise
• 2021: Initiated IPO advisory process for STAR Market listing

Frequently Asked Questions

What types of robots does TMiRob manufacture?

TMiRob produces four main categories of medical service robots: intelligent disinfection robots with triple-mode sterilization, automated delivery systems for hospital logistics, nuclear medicine ward service robots for radiation-isolated environments, and intelligent medical service robots with AI-powered interaction capabilities.

How many hospitals use TMiRob systems?

As of 2025, TMiRob’s products are deployed in more than 400 large tertiary hospitals across 28 provinces and municipalities in China.

Is TMiRob publicly traded?

TMiRob is currently a private company. The company has been undergoing IPO advisory preparations for a potential STAR Market (Science and Technology Innovation Board) listing, having signed advisory agreements with securities firms starting in 2020.

What certifications do TMiRob products hold?

TMiRob’s disinfection robot was the first in China to obtain a disinfection device registration certificate. The nuclear medicine ward service robot was the first medical service robot in China to receive CFDA (now NMPA) Class II medical device registration.